Applications of proteomics in the study of inflammatory bowel diseases

Alex, Philip; Guček, Marjan; Li, Xuhang

doi:10.1002/ibd.20652

Cited by 48 publications

(10 citation statements)

References 136 publications

(193 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This combined with inherent bio logical variations between patient samples further emphasises the importance of achieving sufficient statis tical power [60,61] . It has already been noted that the concentration of candidate IBD biomarkers may be more concentrated in the intestinal tissue compared to serum, potentially reducing the chance of false discoveries.…”

Section: -Dementioning

confidence: 99%

Current application of proteomics in biomarker discovery for inflammatory bowel disease

Chan¹,

Wasinger²,

Leong³

2016

WJGP

View full text Add to dashboard Cite

Recently, the field of proteomics has rapidly expanded in its application towards clinical research with objectives ranging from elucidating disease pathogenesis to discovering clinical biomarkers. As proteins govern and/or reflect underlying cellular processes, the study of proteomics provides an attractive avenue for research as it allows for the rapid identification of protein profiles in a biological sample. Inflammatory bowel disease (IBD) encompasses several heterogeneous and chronic conditions of the gastrointestinal tract. Proteomic technology provides a powerful means of addressing major challenges in IBD today, especially for identifying biomarkers to improve its diagnosis and management. This review will examine the current state of IBD proteomics research and its use in biomarker research. Furthermore, we also discuss the challenges of translating proteomic research into clinically relevant tools. The potential application of this growing field is enormous and is likely to provide significant insights towards improving our future understanding and management of IBD.

show abstract

Section: -Dementioning

confidence: 99%

Current application of proteomics in biomarker discovery for inflammatory bowel disease

Chan¹,

Wasinger²,

Leong³

2016

WJGP

View full text Add to dashboard Cite

show abstract

“…(134–137) Available reviews summarize recent studies and future directions for use of these techniques in greater detail. (138, 139)…”

Section: Investigation Of Future Biomarkersmentioning

confidence: 99%

Biomarkers in inflammatory bowel disease: current practices and recent advances

Iskandar

Ciorba

2012

Translational Research

171

114

View full text Add to dashboard Cite

Crohn’s disease and ulcerative colitis represent the two main forms of the idiopathic chronic inflammatory bowel diseases (IBD). Currently available blood and stool based biomarkers provide reproducible, quantitative tools which can complement clinical assessment to aid clinicians in IBD diagnosis and management. C-reactive protein and fecal based leukocyte markers can help the clinician distinguish IBD from non-inflammatory diarrhea and assess disease activity. The ability to differentiate between forms of IBD and predict risk for disease complications is specific to serologic tests including antibodies against Saccharomyces cerevisiae and perinuclear antineutrophil cytoplasmic proteins. Advances in genomic, proteomic and metabolomic array based technologies are facilitating the development of new biomarkers for IBD. The discovery of novel biomarkers which can correlate with mucosal healing or predict long term disease course has the potential to significantly improve patient care. This article reviews the uses and limitations of currently available biomarkers and highlights recent advances in IBD biomarker discovery.

show abstract

“…Current proteomic approaches are beginning to have a profound impact on the way and capacity by which we profile protein expression and post-translational modifications, functional interactions between proteins and disease biomarkers [19–25]. Very recently, Piras et al [26], investigated the serum proteomic profile of early and advanced CD in order to identify differentially expressed proteins in acute CD and during the disease course.…”

Section: Introductionmentioning

confidence: 99%

Serum Protein Profiling of Adults and Children With Crohn Disease

Vaiopoulou

Gazouli

Papadopoulou

et al. 2015

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

Objectives Crohn’s disease (CD) and ulcerative colitis (UC), known collectively as inflammatory bowel disease (IBD), are chronic immuno-inflammatory pathologies of unknown etiology. Despite the frequent utilization of biomarkers in medical practice, there is a relative lack of information regarding validated paediatric biomarkers for IBD. Further, biomarkers proved to be efficacious in adults are frequently extrapolated to the paediatric clinical setting without considering that the pathogenesis of many diseases is distinctly different in children. In the current study, proteomics technology was employed in order to monitor differences in protein expression among adult and children CD patients, in order to identify a panel of candidate protein biomarkers that might be used to improve prognostic-diagnostic accuracy and to advance paediatric medical care. Methods Male and female serum samples from 12 adults and 12 children with active CD were subjected to two-dimensional gel electrophoresis. Following the relative quantitation of protein spots exhibiting a differential expression between the two groups by densitometry, the spots were further characterized by MALDI-TOF-MS. Results were confirmed by Western blot analysis. Results Clusterin (CLUS) was found to be significantly over-expressed in adults with CD, whereas ceruloplasmin (CERU) and apolipoprotein B-100 (APOB) were found to be significantly over-expressed in children indicating that the expression of these proteins might be implicated in the onset or progression of CD in these two sub-groups of patients. Conclusions Interestingly, we found a differential expression of several proteins in adults versus paediatric CD patients. Undoubtedly, future experiments using a larger cohort of CD patients are needed to evaluate the relevance of our preliminary findings.

show abstract

Applications of proteomics in the study of inflammatory bowel diseases

Cited by 48 publications

References 136 publications

Current application of proteomics in biomarker discovery for inflammatory bowel disease

Current application of proteomics in biomarker discovery for inflammatory bowel disease

Biomarkers in inflammatory bowel disease: current practices and recent advances

Serum Protein Profiling of Adults and Children With Crohn Disease

Contact Info

Product

Resources

About